Jean-François Houvenaghel1, Sophie Drapier2, Joan Duprez3, Gabriel Hadrien Robert4, Audrey Riou2, Dominique Drapier4, Paul Sauleau5, Marc Vérin2. 1. "Behavior and Basal Ganglia" Research Unit (EA 4712), University of Rennes 1, Rennes, France; Department of Neurology, Rennes University Hospital, Rennes, France. Electronic address: jeanfrancois.houvenaghel@chu-rennes.fr. 2. "Behavior and Basal Ganglia" Research Unit (EA 4712), University of Rennes 1, Rennes, France; Department of Neurology, Rennes University Hospital, Rennes, France. 3. "Behavior and Basal Ganglia" Research Unit (EA 4712), University of Rennes 1, Rennes, France. 4. "Behavior and Basal Ganglia" Research Unit (EA 4712), University of Rennes 1, Rennes, France; Department of Psychiatry, Rennes University Hospital, Rennes, France. 5. "Behavior and Basal Ganglia" Research Unit (EA 4712), University of Rennes 1, Rennes, France; Department of Neurophysiology, Rennes University Hospital, Rennes, France.
Abstract
INTRODUCTION: Treatment optimization using continuous subcutaneous apomorphine infusion (CSAI) improves the control of motor fluctuations of patients with Parkinson's disease (PD). Although CSAI seems to be cognitively and behaviorally safe and to improve the quality of life, very few studies have investigated its influence in these domains, especially in patients without cognitive impairment. METHODS: We estimated the impact of CSAI on motor symptoms, cognition, psychiatric domains and quality of life in parkinsonian patients without cognitive impairment by comparing the scores of 22 patients assessed before and 6 months after the start of add-on CSAI. RESULTS: Optimized treatment with CSAI was associated with i) reduced motor fluctuations, ii) unchanged cognition, iii) unchanged psychiatric domains, and iv) improved quality of life in physical and psychological aspects. CONCLUSION: In PD patients without cognitive impairment, CSAI improves motor symptoms and quality of life and, as suggested by previous studies, alters neither cognition nor mental health.
INTRODUCTION: Treatment optimization using continuous subcutaneous apomorphine infusion (CSAI) improves the control of motor fluctuations of patients with Parkinson's disease (PD). Although CSAI seems to be cognitively and behaviorally safe and to improve the quality of life, very few studies have investigated its influence in these domains, especially in patients without cognitive impairment. METHODS: We estimated the impact of CSAI on motor symptoms, cognition, psychiatric domains and quality of life in parkinsonianpatients without cognitive impairment by comparing the scores of 22 patients assessed before and 6 months after the start of add-on CSAI. RESULTS: Optimized treatment with CSAI was associated with i) reduced motor fluctuations, ii) unchanged cognition, iii) unchanged psychiatric domains, and iv) improved quality of life in physical and psychological aspects. CONCLUSION: In PDpatients without cognitive impairment, CSAI improves motor symptoms and quality of life and, as suggested by previous studies, alters neither cognition nor mental health.